Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.
Colin-Leitzinger C et al.
Human Genomics, 2025
Exploring the Genetic Landscape of Primary Marginal Zone Lymphoma of the Urinary Bladder.
Balestri I et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Mechanism of D-type cyclin recognition by the AMBRA1 E3 ligase receptor.
Wang Y et al.
Science Advances, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Peripheral blood somatic mosaicism and clonal hematopoiesis across ancestry backgrounds.
Colin-Leitzinger C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Analysis of CCND3 mutations in diffuse large B-cell lymphoma.
Hua W et al.
Annals of Hematology, 2024
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.
Bai B et al.
Blood Cancer Journal, 2024
Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation.
Kwak JJ et al.
Investigative Ophthalmology & Visual Science, 2023
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R et al.
Signal Transduction and Targeted Therapy, 2023
Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T et al.
Frontiers in Oncology, 2022
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Smith CC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
CRL4AMBRA1 is a master regulator of D-type cyclins.
Simoneschi D et al.
Nature, 2021
Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3.
Yoshida A et al.
Oncogene, 2021
Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.
Mossadegh-Keller N et al.
Frontiers in Immunology, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.
Zhang W et al.
Bmc Cancer, 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y et al.
Ebiomedicine, 2020
Genetic modification of primary human B cells to model high-grade lymphoma.
Caeser R et al.
Nature Communications, 2019
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.
Thompson BJ et al.
The Journal of Experimental Medicine, 2015
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.
Wolfe AL et al.
Nature, 2014
Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.
Oricchio E et al.
The Journal of Experimental Medicine, 2014
F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest.
Chen BB et al.
Oncogene, 2012
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Morin RD et al.
Nature, 2011